In our group we have worked for years on the application of the Nanotechnology advances to the Medicine field.

Nanoparticle-based technology has proven to be an extraordinary tool to develop new drug delivery nanosystems and antigen delivery systems. These systems can be used for the development of nanovaccines and we have worked on new prototypes for the prevention of infectious diseases but also as therapeutics for autoimmune diseases.

To be considered as a candidate for biomedicine purposes, the characterization of the interaction of the nanosystems with a biological environment is indispensable. Related to this, our group has worked hard in the nanotoxicology field, performing several in vitro and in vivo studies to ascertain the possible cytototoxic effect of different nanosystems, prior to its administration in vivo.

We have also applied nanotechnology resources for the development of biosensors with a potential application in clinics to detect serum proteins such as PCR, alpha-phetoprotein, etc. (Biosensor line research).

Our interest is the potential application of nanostructures in the biomedical field:

  • Standarisation of methods to check biocompatibility, toxicity and immunogenicity of nanoparticles. Applying standardized methods (NCL methods), we check biocompatibility, toxicity and immunogenicity of nanoparticles or nanocomposites.
  • Biosensors using antibodies and nanostructures with different applications. Developing of lateral flow biosensors using antibodies and nanostructures with different applications, as detection of C-reactive protein in whole blood samples.
  • Design of nanomaterials.

Projects in this research line: